David Kirn Sells 114,746 Shares of 4D Molecular Therapeutics (NASDAQ:FDMT) Stock

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) insider David Kirn sold 114,746 shares of 4D Molecular Therapeutics stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $10.47, for a total transaction of $1,201,390.62. Following the completion of the sale, the insider directly owned 942,485 shares of the company’s stock, valued at approximately $9,867,817.95. This trade represents a 10.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

David Kirn also recently made the following trade(s):

• On Monday, June 1st, David Kirn sold 1,922 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $10.02, for a total value of $19,258.44.

4D Molecular Therapeutics Trading Up 11.3%

4D Molecular Therapeutics stock traded up $1.18 during midday trading on Tuesday, reaching $11.60. The stock had a trading volume of 2,067,737 shares, compared to its average volume of 784,497. The company has a fifty day moving average price of $9.44 and a two-hundred day moving average price of $9.12. 4D Molecular Therapeutics, Inc. has a 12 month low of $3.68 and a 12 month high of $12.34. The company has a market capitalization of $606.45 million, a P/E ratio of -4.51 and a beta of 2.75.

4D Molecular Therapeutics (NASDAQ:FDMT) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($1.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.04). 4D Molecular Therapeutics had a negative return on equity of 36.83% and a negative net margin of 182.34%.The firm had revenue of $3.05 million during the quarter, compared to the consensus estimate of $2.59 million. On average, equities research analysts predict that 4D Molecular Therapeutics, Inc. will post -3.8 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts recently issued reports on the stock. The Goldman Sachs Group set a $33.00 price target on shares of 4D Molecular Therapeutics in a research report on Friday, May 8th. HC Wainwright restated a “buy” rating and set a $36.00 price objective on shares of 4D Molecular Therapeutics in a report on Friday, March 20th. Chardan Capital reaffirmed a “buy” rating and issued a $26.00 price objective on shares of 4D Molecular Therapeutics in a research note on Thursday, March 19th. Royal Bank Of Canada lifted their price objective on shares of 4D Molecular Therapeutics from $32.00 to $35.00 and gave the company an “outperform” rating in a report on Thursday, March 19th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research report on Monday, April 20th. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $29.88.

Institutional Trading of 4D Molecular Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Evergreen Quality Fund GP Ltd. bought a new position in shares of 4D Molecular Therapeutics in the fourth quarter valued at approximately $7,136,000. Baker BROS. Advisors LP bought a new stake in 4D Molecular Therapeutics during the fourth quarter worth $3,568,000. Armistice Capital LLC boosted its position in 4D Molecular Therapeutics by 76.6% in the fourth quarter. Armistice Capital LLC now owns 1,936,000 shares of the company’s stock worth $14,520,000 after purchasing an additional 840,000 shares during the last quarter. Landing Point Financial Group LLC purchased a new position in 4D Molecular Therapeutics in the fourth quarter worth $142,000. Finally, AXQ Capital LP grew its stake in 4D Molecular Therapeutics by 138.8% in the 4th quarter. AXQ Capital LP now owns 30,755 shares of the company’s stock valued at $231,000 after purchasing an additional 17,876 shares during the period. Hedge funds and other institutional investors own 99.27% of the company’s stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.